Abstract: The present disclosure is directed dye compounds containing a hydrazinyl substituent and optionally, one or more negatively charged groups, such as sulfonate, phosphate, phosphonate, and/or carboxylate groups and dye compounds containing an aminooxy substitutent. The compounds are useful in the detection of analytes containing aldehyde and ketone groups, including, for example, glycans.

Abstract: The invention relates to salt forms of (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(methyl-thiomethyl)pyrrolidin-3-ol, as well as polymorphic forms of the salts. The invention further relates to processes for preparing the salt forms and to the use of the salt forms in the treatment of diseases and disorders where it is desirable to inhibit 5?-methylthioadenosine phosphorylase (MTAP).

Abstract: The invention relates to salt forms of (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(methyl-thiomethyl)pyrrolidin-3-ol, as well as polymorphic forms of the salts. The invention further relates to processes for preparing the salt forms and to the use of the salt forms in the treatment of diseases and disorders where it is desirable to inhibit 5?-methylthioadenosine phosphorylase (MTAP).

Abstract: The present disclosure is directed dye compounds containing a hydrazinyl substituent and optionally, one or more negatively charged groups, such as sulfonate, phosphate, phosphonate, and/or carboxylate groups and dye compounds containing an aminooxy substitutent. The compounds are useful in the detection of analytes containing aldehyde and ketone groups, including, for example, glycans.

Abstract: The invention relates to salt forms of (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(methyl-thiomethyl)pyrrolidin-3-ol, as well as polymorphic forms of the salts. The invention further relates to processes for preparing the salt forms and to the use of the salt forms in the treatment of diseases and disorders where it is desirable to inhibit 5?-methylthioadenosine phosphorylase (MTAP).

Abstract: The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (1) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.

Abstract: Disclosed are various embodiments for automated service interface optimization. In one embodiment, usage metrics are determined for a service client corresponding to usage of a set of data items within a data object. An optimized data object is provided to the service client in response to a request from the service client for the data object. The optimized data object includes empty values in place of one or more data items in the set of data items. The data item(s) are determined based at least in part on the usage metrics.

Abstract: Method and compositions and kits for isolation, identification, and quantification of miRNAs and other small RNAs, including but not limited to, siRNAs, mRNAs, and snRNAs are disclosed. Methods of diagnosing a disease or its progression are also disclosed.

Abstract: The present disclosure is directed dye compounds containing a hydrazinyl substituent and optionally, one or more negatively charged groups, such as sulfonate, phosphate, phosphonate, and/or carboxylate groups and dye compounds containing an aminooxy substitutent. The compounds are useful in the detection of analytes containing aldehyde and ketone groups, including, for example, glycans.

Abstract: The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (1) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to in 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.

Abstract: Methods and systems for protecting websites from cross-site scripting are disclosed. A request for a web page comprising a web page element is received from a client. It is determined if the web page comprises a data integrity token for the web page element. It is also determined if a value of the data integrity token matches an expected value. If the web page comprises the data integrity token and if the value matches the expected value, the web page comprising the web page element is sent to the client. If the web page does not comprise the data integrity token or if the value does not match the expected value, a protective operation is performed.

Abstract: Disclosed are various embodiments for automated service interface optimization. In one embodiment, usage metrics are determined for a service client corresponding to usage of a set of data items within a data object. An optimized data object is provided to the service client in response to a request from the service client for the data object. The optimized data object includes empty values in place of one or more data items in the set of data items. The data item(s) are determined based at least in part on the usage metrics.

Abstract: The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (I) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.

Abstract: Disclosed are various embodiments for automated service interface optimization. In one embodiment, a service client and/or a service provider is reconfigured to use an optimized version of a data transfer interface, where the optimized version transfers fewer data items from the service provider to the service client. In another embodiment, service calls from a service client for multiple different data objects are aggregated into an aggregated service call for a data object. In yet another embodiment, an optimized data object is provided to a service client in response to a request for an unoptimized data object. If the service client attempts to use a data item excluded from the optimized data object, the excluded data item is then provided to the service client.

Abstract: The present invention discloses methods for treating bacterial infections in a subject comprising administering to the subject a sub-growth inhibiting amount of a 5?-methylthioinosine phosphorylase (MTIP) inhibitor, as well as assays for identifying such inhibitors, and compounds and pharmaceutical compositions comprising the inhibitors.

Abstract: Methods and systems for protecting websites from cross-site scripting are disclosed. A request for a web page comprising a web page element is received from a client. It is determined if the web page comprises a data integrity token for the web page element. It is also determined if a value of the data integrity token matches an expected value. If the web page comprises the data integrity token and if the value matches the expected value, the web page comprising the web page element is sent to the client. If the web page does not comprise the data integrity token or if the value does not match the expected value, a protective operation is performed.

Abstract: The invention relates to salt forms of (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(methyl-thiomethyl)pyrrolidin-3-ol, as well as polymorphic forms of the salts. The invention further relates to processes for preparing the salt forms and to the use of the salt forms in the treatment of diseases and disorders where it is desirable to inhibit 5?-methylthioadenosine phosphorylase (MTAP).

Abstract: Disclosed are various embodiments for automated service interface optimization. In one embodiment, a service client and/or a service provider is reconfigured to use an optimized version of a data transfer interface, where the optimized version transfers fewer data items from the service provider to the service client. In another embodiment, service calls from a service client for multiple different data objects are aggregated into an aggregated service call for a data object. In yet another embodiment, an optimized data object is provided to a service client in response to a request for an unoptimized data object. If the service client attempts to use a data item excluded from the optimized data object, the excluded data item is then provided to the service client.

Abstract: Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H. pylori MTAN (5?-methylthioadenosine nucleosidase) to the subject.

Abstract: Disclosed are various embodiments for automated service interface optimization. In one embodiment, a service client and/or a service provider is reconfigured to use an optimized version of a data transfer interface, where the optimized version transfers fewer data items from the service provider to the service client. In another embodiment, service calls from a service client for multiple different data objects are aggregated into an aggregated service call for a data object. In yet another embodiment, an optimized data object is provided to a service client in response to a request for an unoptimized data object. If the service client attempts to use a data item excluded from the optimized data object, the excluded data item is then provided to the service client.